Drug intelligence / Profile preview

NW-401

Development stage: Preclinical
Lead developer: Neowise Biotechnology
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

NW-401 is a preclinical-stage T-cell receptor engineered T-cell (TCR-T) therapy being developed by Neowise Biotechnology. It is designed as a pan-cancer treatment, utilizing the genetic modification of T cells to express specific receptors that recognize and target tumor-associated antigens. The program is currently in the function validation phase of preclinical development. As a cell-based immunotherapy, it aims to harness the patient's immune system to identify and eliminate malignant cells across various cancer types.

Targets

PRAME (Preferentially expressed antigen in melanoma)

Beyond the preview

Go deeper on NW-401.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NW-401.

Explore the full profile